Discovery of (S)-2-((S)-2-(3,5-difluorophenyl)-2hydroxyacetamido)-N-((S,Z)-3-methyl-4-oxo-4,5-dihydro-3H-benzo[d][1,2]diazepin-5-yl)propanamide (BMS-433796):: A γ-secretase inhibitor with Aβ lowering activity in a transgenic mouse model of Alzheimer's disease

被引：25

作者：

Prasad, C. V. C.

Zheng, Ming

Vig, Shikha

Bergstrom, Carl

Smith, David W.

Gao, Qi

Yeola, Suresh

Polson, Craig T.

Corsa, Jason A.

Guss, Valerie L.

Loo, Alice

Wang, Jian

Sleczka, Bogdan G.

Dangler, Charles

Robertson, Barbara J.

Hendrick, Joseph P.

Roberts, Susan B.

Barten, Donna M.

机构：

[1] Bristol Myers Squibb Co, Pharmaceut Res Inst, Dept Discovery Chem, Wallingford, CT 06492 USA

[2] Bristol Myers Squibb Co, Pharmaceut Res Inst, Dept Drug Metab & Pharmacokinet, Wallingford, CT 06492 USA

[3] Bristol Myers Squibb Co, Pharmaceut Res Inst, Dept Analyt R&D, Wallingford, CT 06492 USA

[4] Bristol Myers Squibb Co, Pharmaceut Res Inst, Dept Neurosci Biol, Wallingford, CT 06492 USA

[5] Bristol Myers Squibb Co, Pharmaceut Res Inst, Dept Exploratory Toxicol, Wallingford, CT 06492 USA

[6] Bristol Myers Squibb Co, Pharmaceut Res Inst, Dept Bioanalyt Res, Princeton, NJ 08543 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2007年 / 17卷 / 14期

关键词：

gamma-sectretase inhibitors;

D O I：

10.1016/j.bmcl.2007.04.082

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

We report on the design of benzodiazepin ones as peptidomimetics at the carboxy terminus of hydroxyamides. structure-activity relationships of diazepinones were investigated and orally active gamma-secretase inhibitors were synthesized. Active metabolites contributing to AP reduction were identified by analysis of plasma samples from Tg2576 mice. In particular, (S)-2-((S)-2-(3,5-difluorophenyl)-2-hydroxyacetamido)-N-((S,Z)-3-methyl-4-oxo-4,5-dihydro-3H-benzo[d][1,2]diazepin-5-yl)propanamide (BMS-433796) was identified with an acceptable pharmacodynamic and pharmacokinetic profile. Chronic dosing of BMS-433796 in Tg2576 mice suggested a narrow therapeutic window and Notch-mediated toxicity at higher doses. (C) 2007 Elsevier Ltd. All rights reserved.

引用

页码：4006 / 4011

页数：6

共 30 条

[1] Dynamics of β-amyloid reductions in brain, cerebrospinal fluid, and plasma of β-amyloid precursor protein transgenic mice treated with a γ-secretase inhibitor [J].

Barten, DM ;

Guss, VL ;

Corsa, JA ;

Loo, A ;

Hansel, SB ;

Zheng, M ;

Munoz, B ;

Srinivasan, K ;

Wang, B ;

Robertson, BJ ;

Polson, CT ;

Wang, J ;

Roberts, SB ;

Hendrick, JP ;

Anderson, JJ ;

Loy, JK ;

Denton, R ;

Verdoorn, TA ;

Smith, DW ;

Felsenstein, KM .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 312 (02) :635-643

[2] γ-secretase inhibitors for Alzheimer's disease: Balancing efficacy and toxicity [J].

Barten D.M. ;

Meredith Jr. J.E. ;

Zaczek R. ;

Houston J.G. ;

Albright C.F. .

Drugs in R&D, 2006, 7 (2) :87-97

[3] Presenilin function and γ-secretase activity [J].

Brunkan, AL ;

Goate, AM .

JOURNAL OF NEUROCHEMISTRY, 2005, 93 (04) :769-792

[4] 4-Substituted cyclohexyl sulfones as potent, orally active γ-secretase inhibitors [J].

Churcher, I ;

Beher, D ;

Best, JD ;

Castro, JL ;

Clarke, EE ;

Gentry, A ;

Harrison, T ;

Hitzel, L ;

Kay, E ;

Kerrad, S ;

Lewis, HD ;

Morentin-Gutierrez, P ;

Mortishire-Smith, R ;

Oakley, PJ ;

Reilly, M ;

Shaw, DE ;

Shearman, MS ;

Teall, MR ;

Williams, S ;

Wrigley, JDJ .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (02) :280-284

[5] γ-secretase as a therapeutic target for the treatment of Alzheimer's disease [J].

Churcher, I ;

Beher, D .

CURRENT PHARMACEUTICAL DESIGN, 2005, 11 (26) :3363-3382

[6] Frequency of hippocampal formation atrophy in normal aging and Alzheimer's disease [J].

deLeon, MJ ;

George, AE ;

Golomb, J ;

Tarshish, C ;

Convit, A ;

Kluger, A ;

DeSanti, S ;

McRae, T ;

Ferris, SH ;

Reisberg, B ;

Ince, C ;

Rusinek, H ;

Bobinski, M ;

Quinn, B ;

Miller, DC ;

Wisniewski, HM .

NEUROBIOLOGY OF AGING, 1997, 18 (01) :1-11

[7] Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain [J].

Dovey, HF ;

John, V ;

Anderson, JP ;

Chen, LZ ;

Andrieu, PD ;

Fang, LY ;

Freedman, SB ;

Folmer, B ;

Goldbach, E ;

Holsztynska, EJ ;

Hu, KL ;

Johnson-Wood, KL ;

Kennedy, SL ;

Kholedenko, D ;

Knops, JE ;

Latimer, LH ;

Lee, M ;

Liao, Z ;

Lieberburg, IM ;

Motter, RN ;

Mutter, LC ;

Nietz, J ;

Quinn, KP ;

Sacchi, KL ;

Seubert, PA ;

Shopp, GM ;

Thorsett, ED ;

Tung, JS ;

Wu, J ;

Yang, S ;

Yin, CT ;

Schenk, DB ;

May, PC ;

Altstiel, LD ;

Bender, MH ;

Boggs, LN ;

Britton, TC ;

Clemens, JC ;

Czilli, DL ;

Dieckman-McGinty, DK ;

Droste, JJ ;

Fuson, KS ;

Gitter, BD ;

Hyslop, PA ;

Johnstone, EM ;

Li, WY ;

Little, SP ;

Mabry, TE ;

Miller, FD ;

Ni, B .

JOURNAL OF NEUROCHEMISTRY, 2001, 76 (01) :173-181

[8] THE ASYMMETRIC-SYNTHESIS OF ALPHA-AMINO-ACIDS - ELECTROPHILIC AZIDATION OF CHIRAL IMIDE ENOLATES, A PRACTICAL APPROACH TO THE SYNTHESIS OF (R)-ALPHA-AZIDO AND (S)-ALPHA-AZIDO CARBOXYLIC-ACIDS [J].

EVANS, DA ;

BRITTON, TC ;

ELLMAN, JA ;

DOROW, RL .

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1990, 112 (10) :4011-4030

[9]

GALLEY G, 2006, Patent No. 7060698

[10] 3-Substituted gem-cyclohexane sulfone based γ-secretase inhibitors for Alzheimer's disease:: Conformational analysis and biological activity [J].

Jelley, Richard A. ;

Elliott, Jason ;

Gibson, Karl R. ;

Harrison, Timothy ;

Beher, Dirk ;

Clarke, Earl E. ;

Lewis, Huw D. ;

Shearman, Mark ;

Wrigley, Jonathan D. J. .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (14) :3839-3842

← 1 2 3 →